SCHEMBL994584

SCHEMBL994584

CC(C)(C)OC(=O)NCC(N)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.53
GAA P10253 1/20 0.53
KMT2A Q03164 1/20 0.53
GFPT1 Q06210 1/20 0.47
TDP1 Q9NUW8 1/20 0.43
SYK P43405 1/20 0.42
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
CTSS P25774 4/20 0.41
CTSK P43235 4/20 0.41
CTSL P07711 1/20 0.41
CTSB P07858 1/20 0.41
SLC7A5 Q01650 1/20 0.39
SERPINE1 P05121 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CASR P41180 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL997508 1.00 MEN1 (0.53) MEN1GAAKMT2AGFPT1TDP1
SCHEMBL994583 1.00 MEN1 (0.53) MEN1GAAKMT2AGFPT1TDP1
Hydrochloric Acid SCHEMBL2680968 0.98 MEN1 (0.51) MEN1GAAKMT2AGFPT1TDP1
Hydrochloric Acid SCHEMBL668972 0.98 MEN1 (0.51) MEN1GAAKMT2AGFPT1TDP1
Hydrochloric Acid SCHEMBL2681229 0.98 MEN1 (0.51) MEN1GAAKMT2AGFPT1TDP1
Chloromethane SCHEMBL17911911 0.98 MEN1 (0.51) MEN1GAAKMT2AGFPT1TDP1
Formic Acid SCHEMBL7370577 0.93 MEN1 (0.47) MEN1GAAKMT2AGFPT1TDP1
SCHEMBL23455458 0.89 MEN1 (0.46) MEN1GAAKMT2AGFPT1TDP1
SCHEMBL23455605 0.89 MEN1 (0.46) MEN1GAAKMT2AGFPT1TDP1
SCHEMBL13365413 0.86 MEN1 (0.47) MEN1GAAKMT2AGFPT1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112125819-B Preparation method of dencichine 兰州百源基因技术有限公司 2023-07-25 CN claimed
CN-112125819-A Preparation method of sanchinin 兰州百源基因技术有限公司 2020-12-25 CN claimed
CN-109748813-A A kind of synthetic method improvement of dencichine 西安格硕信息科技有限公司 2019-05-14 CN claimed
CN-105061247-A Improved synthesis method for dencichine XI AN YUEDA PLANT SCIENCE AND TECHNOLOGY CO LTD 2015-11-18 CN claimed
EP-1506970-A1 COMPOUNDS WHICH CAN BLOCK THE RESPONSE TO CHEMICAL SUBSTANCES OR THERMAL STIMULI OR MEDIATORS OF INFLAMMATION OF NOCICEPTORS, PRODUCTION METHOD THEREOF AND COMPOSITIONS CONTAINING SAME Diverdrugs, S.L. (ES) 2005-02-16 EP claimed
EP-4719381-A1 LIGAND-POLAR DRUG CONJUGATES Tripartite Therapeutics Inc. (TW) 2026-04-08 EP disclosed
EP-3681875-B1 CYCLIC PEPTIDE ANTIBIOTICS HOFFMANN LA ROCHE (CH) 2026-01-14 EP disclosed
CN-111148739-B Cyclic peptide antibiotics 豪夫迈·罗氏有限公司 2025-06-03 CN disclosed
EP-4548937-A1 ANTIBODY-DRUG COMPLEX Eisai R&D Management Co., Ltd. (JP) 2025-05-07 EP disclosed
US-20250129125-A1 MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2025-04-24 US disclosed
US-12195796-B2 Cyclooctatetraene containing dyes and compositions ILLUMINA CAMBRIDGE LIMITED (GB) 2025-01-14 US disclosed
US-20250009915-A1 NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF FUJIFILM CORPORATION (JP) 2025-01-09 US disclosed
US-6204282-B1 TREATING CANCER, RETINOPATHY, ATHEROSCLEROSIS, VASCULAR RESTENOSIS, OR OSTEOPOROSIS. SCHERING CORPORATION 2001-03-20 US disclosed
WO-2000032578-A1 BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS SCHERING CORPORATION (US) 2000-06-08 WO disclosed
EP-0970950-A2 Novel isoxazoline and isoxazole fibrinogen receptor antagonists DuPont Pharmaceuticals Company (US) 2000-01-12 EP disclosed
EP-0832076-A1 NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1998-04-01 EP disclosed
CN-1138322-A 2,3-diaminopropionic acid derivative SUMITOMO PHARMA (JP) 1996-12-18 CN disclosed
EP-0664711-A1 PEPTIDE INHIBITORS OF CELLULAR ADHESION CENTOCOR INC. (US) 1995-08-02 EP disclosed
WO-1994005310-A1 PEPTIDE INHIBITORS OF CELLULAR ADHESION CENTOCOR, INC. (US) 1994-03-17 WO disclosed
EP-0350163-A2 Renin inhibitory peptides BEECHAM GROUP PLC (GB) 1990-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129125-A1 MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF PAICS, CYCS, LSS MEN1 495/4885GAA 1370/4885KMT2A 2834/4885
US-20250009915-A1 NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF SLC39A3, SLC39A14, SLC39A11 MEN1 45/4885GAA 4491/4885KMT2A 1691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.